Open Orphan to start first-ever coronavirus challenge trial

0
31
  • Open Orphan lands GBP8.1mln contract as hVIVO arm gears up for asthma challenge study
  • Open Orphan moves forward with government-backed COVID-19 vaccine human challenge study
  • Open Orphan say it’s ‘exciting times’ after announcing GBP8.1mln contract for asthma challenge study
Open Orphan

Quick facts: Open Orphan PLC

Follow

View company profile

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands.

24 Aug 2021

(, ) said its hVIVO arm has won an GBP8.1mln contract with an unnamed ‘major global pharmaceutical company’ to test an antiviral product using its asthma human challenge study model.

It will use as the challenge agent the human rhinovirus, the most prevalent cause of the common cold, which can exacerbate the symptoms of asthma, a condition suffered by 5.4mln people in the UK.

Financially, the bulk of the revenues from the deal will be recognised this year and next. Work will get underway in the first half of next year.

Open Orphan said this latest contract underlined the “increased international focus [on] and investment into respiratory and infectious diseases following the outbreak of COVID-19”.

Read more

09 Aug 2021

(, ) () said its hVIVO operation has successfully developed a malaria challenge model that will be used to help develop the next generation of drugs and vaccines from November.

Its scientists will deploy a P. falciparum sporozoite (PfSPZ) challenge agent that has been used in “multiple” clinical trials in the UK, US, Europe, Indonesia and Africa.

Read more

29 Jul 2021

(, ) secured a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness.

Its subsidiary Venn Life Sciences will provide Data Management & Biostatistics services to support the Phase II trial of an antibiotic drug candidate for Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research organisation developing new affordable and patient-friendly treatments for neglected patients around the world.

Read more

21 Oct 2020

‘s () hVIVO arm has this week been confirmed as key player in the quest for a COVID-19 vaccine.

The business has just won a multi-million-pound UK government contract for human challenge studies, where healthy participants are exposed to the virus to get infected.

Read more

24 Aug 2021

(, ) (AIM:ORPH, ) Cathal Friel joins Proactive London after announcing their hVIVO arm has won an GBP8.1mln contract with an unnamed ‘major global pharmaceutical company’ to test an antiviral product using its asthma human challenge study model.

It will use as the challenge agent the human rhinovirus, the most prevalent cause of the common cold, which can exacerbate the symptoms of asthma, a condition suffered by 5.4mln people in the UK.

Friel also discusses their Malaria challenge study model which recently launched and the possibility of malaria challenge study contracts.

02 Jun 2021

ORPH has firmly established its core pharma services offering, underpinned by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over GBP100mln. This is in addition to substantial contracts already signed with the UK Government for COVID-19 vaccine challenge studies, pending finalisation of the characterisation study anticipated imminently. Furthermore, after extensive integration and restructuring in the past 18 months the company was finally profitable in the fourth quarter (Q4) of 2020 and continues during 2021 to perform very strongly according to plans. The company is also advancing its strategy of maximising the value of its non-core intellectual property (IP) assets to return value to existing shareholders. ORPH has received legal approval for a capital reduction relating to the current or future demerger of its non-core assets via spin-off into separately listed companies, to grant new share allotments or dividends, potentially crystallising the value of these assets.

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan say it’s ‘exciting times’ after announcing GBP8.1mln contract for…

Open Orphan PLC (AIM:ORPH, FRA:CRO) (AIM:ORPH, FRA:CRO) Cathal Friel joins Proactive London after announcing their hVIVO arm has won an GBP8.1mln contract with an unnamed ‘major global pharmaceutical company’ to test an antiviral product using its asthma human challenge study model.

It will use…

19 hours, 34 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here